Moolec Science (MLECW) Other Operating Expenses (2022 - 2024)
Moolec Science (MLECW) posted Other Operating Expenses of $4.6 million for Q2 2023, up 411.68% sequentially from $906746.0 in Q1 2023, and up 242.18% YoY from $1.4 million in Q2 2022.
Moolec Science (MLECW) Other Operating Expenses (2022 - 2024) Analysis & Trends
Moolec Science has reported Other Operating Expenses for 2 years, with the latest figure at $4.6 million in Q2 2023.
- Quarterly Other Operating Expenses rose 242.18% year-over-year to $4.6 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $4.6 million (up 296.89% YoY) and the FY2024 annual result came in at -$703265.0, down 166.64% from the prior year.
- Other Operating Expenses grew to $4.6 million in Q2 2023 per MLECW's latest filing, from $906746.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $4.6 million in Q2 2023 and troughed at -$3.3 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -15,427.00 |
| Sep 30, 2024 | -7,367.00 |
| Jun 30, 2024 | -2,897.00 |
| Mar 31, 2024 | -30,987.00 |
| Dec 31, 2023 | -20,924.00 |
| Sep 30, 2023 | -17,909.00 |
| Jun 30, 2023 | 4.64 Mn |
| Mar 31, 2023 | 906,746.00 |
| Jun 30, 2022 | -3.26 Mn |
| Mar 31, 2022 | -26,649.00 |